undamentalytics Newsletter
Sign in

Capricor Therapeutics, Inc. (CAPR) stock

Add to watchlist

Add holding +

NASDAQ: CAPR Nasdaq Biotechnology Next results ~November 10, 2026

Capricor Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Capricor Therapeutics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 3 selling0 purchases and 13 sales by directors and officers, last 12 monthsInsider trades
  • Funds96 adding, 80 cuttingOf 36 active managers that changed their stake, 20 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 10, 2026 (estimated)

Current signal Revenue growth decelerating: TTM revenue growth slowed to -11.5% (-76.9pp vs the prior quarter), the 2nd consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 9 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 11.5% over the last 12 months.
  • Growth slowing. The growth rate is 76.9 points lower than a quarter earlier.
  • Loss-making. Operating margin is -191.1%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 95.5 points on a year ago.
  • Burning cash. Free cash flow was -184.8% of revenue over the last 12 months.

Latest results: FY2024 Q4

Filed March 17, 2026
Earnings per share
-$0.70 against an average estimate of -$0.58: missed by 21.6%
Revenue
$11m, down 7.9% on a year earlier
Share reaction
+58.7% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500
Next report
November 10, 2026; average EPS estimate -$0.41

Capricor Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+13.5%
  • 1 week+26.1%
  • 1 month-19.1%
  • This year-74.9%
  • 1 year+11.2%
  • 5 years+87.6%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

EPS (TTM, diluted)
$-2.47

Growth

Share count change
+24.2%

Earnings

Last results
August 13, 2026
Next results (est.)
November 9, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Results
  3. Announcement
  4. Announcement
  5. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Capricor Therapeutics, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Moat

8 /100

Weak moat

How hard Capricor Therapeutics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -48.7% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -407.5%; its worst year was -6190.2%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 10 years, at a median -419.5% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 598.6% over five years; stock-based pay has been a median 50.8% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (12 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 10, 2026, after the close. Analysts expect revenue of $10m and EPS of −$0.41 (range −$0.74 to $0.87) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.45 +36% $56m 0%
Next −$1.45 +0% $57m +2%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +553.5% on 90 days ago. In the last 30 days, 0 analysts raised Capricor Therapeutics, Inc.'s forecast and 7 cut it.

Consensus EPS forecast Capricor Therapeutics, Inc., last 90 days
−$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.22 Current fiscal year, 60 days ago: −$1.05 Current fiscal year, 30 days ago: −$2.27 Current fiscal year, 7 days ago: −$1.45 Current fiscal year, Now: −$1.45 −$1.45 Next fiscal year, 90 days ago: −$0.64 Next fiscal year, 60 days ago: −$1.26 Next fiscal year, 30 days ago: −$1.48 Next fiscal year, 7 days ago: −$1.48 Next fiscal year, Now: −$1.45 −$1.45

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.22−$0.64
60 days ago −$1.05−$1.26
30 days ago −$2.27−$1.48
7 days ago −$1.45−$1.48
Now −$1.45−$1.45

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.58 −$0.70 −21.6%
Dec 2025 −$0.55 −$0.62 −12.4%
Sept 2025 −$0.54 −$0.54 +0.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

10 analysts, Oct 2026
Buy440%
Hold660%
Sell00%

Monthly trend

  1. Oct 202613610
  2. Sep 202613610
  3. Aug 2026279
  4. Jul 20261010

Counts of recommendations published by analysts covering Capricor Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
37.7%
of tradable shares
Days to cover
5.5
at average volume
Short interest, 1 month
+1%
to October 15, 2026
Held by institutions
74%
of shares
Held by insiders
9.4%
of shares
Employees
231
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
CAPR−15%+32%+27%+182%+109%−75%
Industry peers (median)−36%−57%−18%−29%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
CAPR25%50%58%50%50%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
CAPR−64%−49%−66%−50%−71%−89%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 98% from June 16, 2016 to March 10, 2020. Getting back needed a 4953% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$3.85 – $35.34
From 52-week high
−79.5%
vs 50-day average
−10.3%
vs 200-day average
−64.8%
Volatility (1 year)
393%
Beta vs S&P 500
0.87

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±12.1%
After a week
6 up, 6 down
typical move ±18.0%
After a month
6 up, 6 down
typical move ±63.5%
Results releasedNext dayS&P 500 next day5 days21 days
August 13, 2026 +58.7% +0.5% +63.2% +110.3%
May 12, 2026 −4.9% +0.4% −15.6% −21.5%
March 12, 2026 −9.1% −2.1% −7.1% +2.9%
November 10, 2025 +4.6% +1.8% −4.0% +383.5%
August 11, 2025 −11.4% +0.9% −15.1% −30.2%
May 13, 2025 +7.9% +0.8% +54.9% +96.1%
March 19, 2025 +23.7% +0.8% +13.5% −3.1%
November 13, 2024 +2.2% −0.6% +4.5% −26.7%
October 16, 2024 −14.4% +0.4% −1.0% −14.4%
August 7, 2024 −0.8% +1.6% −2.3% +4.3%
May 13, 2024 −1.9% +0.5% +18.9% −4.5%
February 29, 2024 +5.5% +1.3% +16.4% +64.0%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Capricor Therapeutics, Inc.
$0 $10M $20M $30M FY20 Q4 FY21 Q3 FY23 Q3 FY24 Q4 Revenue (TTM), FY20 Q4: $310.3K Revenue (TTM), FY21 Q1: $165.4K Revenue (TTM), FY21 Q2: $319.6K Revenue (TTM), FY21 Q3: $302.7K Revenue (TTM), FY21 Q4: $244.9K Revenue (TTM), FY23 Q2: $9.5M Revenue (TTM), FY23 Q3: $14M Revenue (TTM), FY23 Q4: $25.2M Revenue (TTM), FY24 Q1: $27.1M Revenue (TTM), FY24 Q2: $27.2M Revenue (TTM), FY24 Q3: $23.2M Revenue (TTM), FY24 Q4: $22.3M $22.3M

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY20 Q4 $310.3K
FY21 Q1 $165.4K
FY21 Q2 $319.6K
FY21 Q3 $302.7K
FY21 Q4 $244.9K
FY23 Q2 $9.5M
FY23 Q3 $14M
FY23 Q4 $25.2M
FY24 Q1 $27.1M
FY24 Q2 $27.2M
FY24 Q3 $23.2M
FY24 Q4 $22.3M
Revenue growth, TTM YoY Capricor Therapeutics, Inc.
-100% 0% 100% 200% FY19 Q4 FY20 Q3 FY21 Q2 FY24 Q4 Revenue growth, TTM YoY, FY19 Q4: -39.9% Revenue growth, TTM YoY, FY20 Q1: -36.1% Revenue growth, TTM YoY, FY20 Q2: -60.2% Revenue growth, TTM YoY, FY20 Q3: -66.8% Revenue growth, TTM YoY, FY20 Q4: -69.1% Revenue growth, TTM YoY, FY21 Q1: -82.8% Revenue growth, TTM YoY, FY21 Q2: -46.7% Revenue growth, TTM YoY, FY21 Q3: -36.2% Revenue growth, TTM YoY, FY21 Q4: -21.1% Revenue growth, TTM YoY, FY24 Q2: 187.2% Revenue growth, TTM YoY, FY24 Q3: 65.3% Revenue growth, TTM YoY, FY24 Q4: -11.5% -11.5%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY19 Q4 -39.9%
FY20 Q1 -36.1%
FY20 Q2 -60.2%
FY20 Q3 -66.8%
FY20 Q4 -69.1%
FY21 Q1 -82.8%
FY21 Q2 -46.7%
FY21 Q3 -36.2%
FY21 Q4 -21.1%
FY24 Q2 187.2%
FY24 Q3 65.3%
FY24 Q4 -11.5%
Operating margin (TTM) Capricor Therapeutics, Inc.
-15000% -10000% -5000% 0% FY20 Q4 FY21 Q3 FY23 Q3 FY24 Q4 Operating margin (TTM), FY20 Q4: -4412.6% Operating margin (TTM), FY21 Q1: -10124.7% Operating margin (TTM), FY21 Q2: -5738.2% Operating margin (TTM), FY21 Q3: -6190.2% Operating margin (TTM), FY21 Q4: -8549.9% Operating margin (TTM), FY23 Q2: -322.3% Operating margin (TTM), FY23 Q3: -219.7% Operating margin (TTM), FY23 Q4: -95.6% Operating margin (TTM), FY24 Q1: -96.5% Operating margin (TTM), FY24 Q2: -110.5% Operating margin (TTM), FY24 Q3: -155.6% Operating margin (TTM), FY24 Q4: -191.1% -191.1%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY20 Q4 -4412.6%
FY21 Q1 -10124.7%
FY21 Q2 -5738.2%
FY21 Q3 -6190.2%
FY21 Q4 -8549.9%
FY23 Q2 -322.3%
FY23 Q3 -219.7%
FY23 Q4 -95.6%
FY24 Q1 -96.5%
FY24 Q2 -110.5%
FY24 Q3 -155.6%
FY24 Q4 -191.1%
FCF margin (TTM) Capricor Therapeutics, Inc.
-8000% -6000% -4000% -2000% 0% FY20 Q4 FY21 Q3 FY23 Q3 FY24 Q4 FCF margin (TTM), FY20 Q4: -3417.4% FCF margin (TTM), FY21 Q1: -7710.2% FCF margin (TTM), FY21 Q2: -4838.5% FCF margin (TTM), FY21 Q3: -5331.5% FCF margin (TTM), FY21 Q4: -7352.3% FCF margin (TTM), FY23 Q2: -206.5% FCF margin (TTM), FY23 Q3: -159.1% FCF margin (TTM), FY23 Q4: -106.9% FCF margin (TTM), FY24 Q1: -120.5% FCF margin (TTM), FY24 Q2: -130.5% FCF margin (TTM), FY24 Q3: -163.7% FCF margin (TTM), FY24 Q4: -184.8% -184.8%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period FCF margin (TTM)
FY20 Q4 -3417.4%
FY21 Q1 -7710.2%
FY21 Q2 -4838.5%
FY21 Q3 -5331.5%
FY21 Q4 -7352.3%
FY23 Q2 -206.5%
FY23 Q3 -159.1%
FY23 Q4 -106.9%
FY24 Q1 -120.5%
FY24 Q2 -130.5%
FY24 Q3 -163.7%
FY24 Q4 -184.8%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025
Income
Revenue 1 0 1 5 6 4 3 2 1 0 0 3 25 22 0
EBITDA −5 −2 −7 −6 −13 −17 −13 −15 −8 −14 −21 −29 −23 −41 −106
Operating income −5 −2 −7 −6 −13 −17 −13 −15 −8 −14 −21 −30 −24 −43 −108
Net income −1 −2 −9 −6 −13 −19 2 −15 −8 −14 −20 −29 −22 −40 −105
Diluted EPS −$0.33 −$0.53 −$2.13 −$1.32 −$2.02 −$2.52 $0.23 −$0.13 −$0.52 −$0.88 −$0.87 −$1.18 −$0.83 −$1.15 −$2.26
Growth (year on year)
Revenue — −85.6% +157.4% +851.2% +15.3% −27.5% −33.3% −37.3% −39.9% −69.1% −21.1% +941.8% +886.8% −11.5% −100.0%
Net income — — — — — — — −724.8% — — — — — — —
Diluted EPS — — — — — — — −157.8% — — — — — — —
Margins
EBITDA margin −361.1% <−999% <−999% −124.8% −226.6% −421.4% −477.0% −907.6% −752.4% <−999% <−999% <−999% −91.4% −184.7% —
Operating margin −361.7% <−999% <−999% −125.7% −228.6% −424.6% −482.4% −917.0% −769.5% <−999% <−999% <−999% −95.6% −191.1% —
Net margin −84.9% <−999% <−999% −129.9% −233.0% −470.3% 91.2% −908.9% −760.4% <−999% <−999% <−999% −88.5% −181.7% —
Free-cash-flow margin −343.4% <−999% <−999% 16.6% −198.4% −366.3% −534.9% −848.3% −678.7% <−999% <−999% 114.3% −106.9% −184.8% —
Cash flow
Cash from operations −5 −2 −6 1 −11 −14 −14 −14 −7 −10 −17 5 −26 −40 −70
Capital spending 0 0 0 0 0 0 0 0 0 1 1 2 1 1 3
Free cash flow −5 −2 −6 1 −11 −15 −14 −14 −7 −11 −18 3 −27 −41 −73
Stock-based pay 1 0 0 0 2 2 2 2 1 2 3 4 7 10 17
Free cash flow after stock pay −5 −3 −6 0 −13 −17 −16 −16 −8 −13 −21 −2 −34 −51 −90
Balance sheet
Cash 2 0 2 8 6 3 6 4 4 33 35 10 15 11 288
Total debt 0 0 0 0 0 0 0 0 0 0 3 3 3 3 0
Net debt (negative = net cash) −2 −0 −2 −8 −6 −3 −6 −4 −4 −32 −32 −6 −11 −8 −288
Diluted shares 15m 4m 4m 5m 6m 7m 11m 12m 15m 16m 23m 25m 27m 35m 46m
Returned to shareholders
Buybacks — — — — — — — 0 0 0 — — — — —
Total returned — — — — — — — 0 0 0 — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Dividends, buybacks and capital spending

Diluted share count
+24.2%
year over year

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated CAPR JANX CRSP ABEO SCYX CELU Median
Revenue, last 12 months $22m $24m $25m $26m $19m $19m $55m
Revenue growth, last 12 months −11.5% >999% −34.3% −87.7% 489.8% −58.1% 12.2%
Revenue growth, 3-year average 260.7% 45.7% −47.1% 212.0% −47.9% 7.2% 14.3%
Revenue growth, latest quarter −7.9% >999% >999% >999% −82.8% −5.3% 10.2%
Gross margin — — — 67.1% 26.0% 19.2% 82.9%
Operating margin −191.1% −598.1% <−999% −327.6% −117.6% −264.3% −190.3%
Operating margin, 3-year average <−999% <−999% <−999% <−999% −592.1% −204.2% −365.3%
Net margin −181.7% −427.5% <−999% −246.4% −53.3% −245.7% −172.8%
Cash from operations / revenue −179.6% −171.9% <−999% −299.5% −69.3% −47.8% −168.8%
Free-cash-flow margin −184.8% −174.7% <−999% −319.5% −69.3% −80.1% −168.1%
Free-cash-flow margin, 3-year average <−999% <−999% −793.9% <−999% −304.8% −50.3% −313.4%
Stock pay / revenue 43.8% 153.7% 276.8% 45.4% 12.3% 66.5% 20.7%
Change in share count 24.2% 6.2% 10.0% 36.6% 1.9% 24.7% 8.3%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$941M
Institutions reporting
168
Shares held vs prior quarter
▲ 15.3%
Positions opened / closed
26 / 35

Top buyers and sellers, Q2 2026: 96 institutions bought and 80 sold ; the biggest buyer was State Street Corp (+1.2M shares) and the biggest seller Point72 Asset Management, L.P (−726K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $99.8M 4.1M 10.6% ▲ 21.1%
Tang Capital Management LLC $98.7M 4.1M 10.5% ▲ 20.6%
Montanova Capital, LLC $98.6M 4.1M 10.5% ▲ 7.2%
State Street Corp $81.8M 3.4M 8.7% ▲ 55.7%
Vanguard Capital Management LLC $55.3M 2.3M 5.9% ▲ 13.3%
Goldman Sachs Group Inc $38M 1.6M 4.0% ▲ 73.0%
RA Capital Management, L.P. $36.3M 1.5M 3.9% 0.0%
Boxer Capital Management, LLC $33.6M 1.4M 3.6% ▲ 136.5%
Geode Capital Management, LLC $33M 1.4M 3.5% ▲ 22.7%
FMR LLC $27.4M 1.1M 2.9% ▲ 47.3%
Citadel Advisors LLC $19.6M 814K 2.1% ▲ 51.0%
Mercer Global Advisors Inc $19.3M 803K 2.1% ▲ 99.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Capricor Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $8.4M 13 trades by 3 insiders · 100% under pre-set plans
Net ▼ $8.4M net selling
Insider Date Trade Shares Price Value
Bergmann Anthony CHIEF FINANCIAL OFFICER June 25, 2026 Sell pre-set plan 24,100 $30.38 $732,158
Krasney Karen EVP, GENERAL COUNSEL June 25, 2026 Sell pre-set plan 24,100 $30.38 $732,158
Bergmann Anthony CHIEF FINANCIAL OFFICER June 24, 2026 Sell pre-set plan 400 $30.00 $12,000
Krasney Karen EVP, GENERAL COUNSEL June 24, 2026 Sell pre-set plan 400 $30.00 $12,000
Bergmann Anthony CHIEF FINANCIAL OFFICER June 22, 2026 Sell pre-set plan 500 $30.00 $15,000
Krasney Karen EVP, GENERAL COUNSEL June 22, 2026 Sell pre-set plan 500 $30.00 $15,000
Bergmann Anthony CHIEF FINANCIAL OFFICER May 1, 2026 Sell pre-set plan 25,000 $31.70 $792,500
Krasney Karen EVP, GENERAL COUNSEL May 1, 2026 Sell pre-set plan 25,000 $31.70 $792,500
Sabar Karimah Es Director April 2, 2026 Sell pre-set plan 7,529 $32.00 $240,928
Sabar Karimah Es Director April 1, 2026 Sell pre-set plan 53,735 $31.03 $1.7M
Bergmann Anthony CHIEF FINANCIAL OFFICER March 31, 2026 Sell pre-set plan 25,000 $30.13 $753,250
Sabar Karimah Es Director March 31, 2026 Sell pre-set plan 61,265 $30.17 $1.8M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 2 trades and filings

No trades in Capricor Therapeutics, Inc. disclosed in the last 12 months; 2 earlier trades on record.

  • Roger Marshall(R-KS 1):Purchase, $1,001 - $15,000, traded July 27, 2017, filed August 6, 2018
  • Roger Marshall(R-KS 1):Sale (full), $1,001 - $15,000, traded July 27, 2017, filed August 6, 2018

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around November 9, 2026 estimated from the company's past filing pattern, not announced

  • August 13, 2026
  • May 12, 2026
  • March 12, 2026
  • November 10, 2025
  • August 11, 2025
  • May 13, 2025

Recent SEC filings

Data status

When each part of this page on Capricor Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Capricor Therapeutics, Inc. in brief

What does Capricor Therapeutics, Inc. do?
Capricor Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Capricor Therapeutics, Inc.'s stock ticker?
Capricor Therapeutics, Inc. trades under the ticker CAPR on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Capricor Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Tang Capital Management LLC and Montanova Capital, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Capricor Therapeutics, Inc.'s market cap?
On December 31, 2025, Capricor Therapeutics, Inc.'s market capitalisation was about $1.3B and net debt of -$288M. Market figures come from third-party market data and may be delayed.
Who are Capricor Therapeutics, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Capricor Therapeutics, Inc. are Janux Therapeutics, Inc., Crispr Therapeutics AG, Abeona Therapeutics Inc., Scynexis Inc and Celularity Inc. The side-by-side comparison below sets their revenue, margins and growth against Capricor Therapeutics, Inc.'s.
Are insiders buying or selling Capricor Therapeutics, Inc. stock?
Over the last 12 months, Capricor Therapeutics, Inc.'s directors and officers reported 0 open-market purchases and 13 sales on Form 4. The insider trading page charts every trade.
When is Capricor Therapeutics, Inc.'s next earnings date?
Around November 10, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Capricor Therapeutics, Inc. announces its own schedule.